Abstract:
CD200 is a transmembrane molecule with an important immunoregulatory role that is overexpressed on most chronic lymphocytic leukemia (CLL) cells. In this study, we characterized a previously unknown soluble form of this molecule in human plasma termed sCD200. Levels of sCD200 were elevated in the plasma of CLL patients compared with healthy controls and there was a significant correlation with CLL disease stage. Infusion of sCD200hi CLL plasma into severely immunocompromised NOD.SCIDγcnull mice enhanced the engraftment of CLL splenocytes, as compared to mice receiving sCD200lo normal plasma. CLL cells were detected in both the spleen and peritoneal cavity of animals for up to 75 days. Engraftment of CLL cells did not occur after infusion of CLL plasma depleted of sCD200 and was abolished in mice treated with anti-CD200 or OKT3 mAb, suggesting a role for both sCD200 and T cells in CLL engraftment. Notably, anti-CD200 mAb was as effective as rituximab in eliminating engrafted CLL cells when administered 21 days after engraftment. Taken together, our findings point to sCD200 as a novel prognostic marker and therapeutic target for CLL.
Further, the humanized mouse model described here may prove valuable to preclinically assess new treatment regimens for CLL. The CLL microenvironment is crucial for CLL survival and proliferation (7) .
Introduction
Non-malignant constituents of the microenvironment, mostly T cells, mesenchymal stromal cells (MSCs), and CD14 + nurse-like cells (NLCs) provide antigenic signals, cytokines, and other CLL survival factors such as BAFF, to support CLL survival and proliferation (8) (9) (10) (11) . T cells in the CLL microenvironment are also known to express CD40L, which, through stimulation of CD40 on CLL cells, induces CLL proliferation and anti-apoptotic pathways (12) . A number of studies have shown that CLL cells can directly modulate T cell function by expression of cell-surface molecules and/or 4 production of soluble factors (13, 14) . Based on these data, we hypothesized that CD200 may be one of the important factors modulating the CLL microenvironment (2, 3, 5) .
A number of membrane-bound molecules with immunomodulatory functions are known to exist also in soluble forms where they are believed to play a functional role in a number of disease states, including cancer. In CLL, soluble forms of CD23, CD44, and CD14 have been reported to augment the survival of CLL cells in vitro (15) (16) (17) . We found that CD200 could be shed from CLL cells after stimulation by PMA and TLR7
agonists, inferring that a soluble form of CD200 (sCD200) might be present in human plasma including that of CLL patients (6) . The studies described below were designed to investigate if soluble CD200 levels were increased in CLL patients relative to healthy controls, and whether those levels were related to disease stage. We also investigated whether sCD200 present in CLL patient plasma might contribute to growth/survival of CLL cells in NOD.SCIDγ c null mice.
Material and methods

Mice:
NOD.SCIDγ c null (NSG) mice were bred and maintained under sterile conditions at the Toronto Medical Discovery Tower, MaRs Centre. All mice were used at 8-13 weeks of age.
Human splenocytes and CLL cells
The spleen from consenting patients undergoing splenectomy at Sunnybrook Health Science Centre was harvested at surgery and single cell suspensions prepared in AIMV medium (Invitrogen, Carlsbad, CA). Cells were washed (x2), counted and stored Cells recovered after centrifugation were resuspended in PBS at appropriate concentrations for injection.
In some experiments where cells from the peripheral blood of CLL patients were used for reconstitution, CD19 + CD5 + CLL cells were purified from fresh blood as described previously (18) . All protocols were approved by institutional review boards.
Human plasma
Plasma samples from 82 patients diagnosed with CLL at Sunnybrook Health Science Centre from 1996-2008 (Table I) were stored at -20°C and used for retrospective analysis of sCD200 levels in CD200 ELISA (see below).
For in vivo studies in NSG mice, plasma obtained at routine clinical follow-up from a group of patients at late disease stage (Rai Stage III-IV), and/or with high white cell count, were pooled into batches (>8 donors/batch). The control plasma used was pooled from a group of 10 healthy volunteers. sCD200 levels in all plasma samples were assessed by CD200 ELISA. sCD200 levels in pooled normal plasma were in the range 0.5 +0.2 ng/ml while in various pooled CLL plasma batches levels were consistently ~10-fold higher (5.0 ±1.3 ng/ml). Where absorbed plasma was used, the pooled CLL plasma was absorbed overnight at 4°C with anti-CD200 (1B9)-conjugated CNBr-activated High binding 96-well EIA/RIA plates (Corning Life Sciences) were coated with the capture anti-CD200 mAb1B9 at 1.25μg/ml overnight at 4°C in Tris-HCI, pH 8.1.
Plates were then blocked for 1 hour at room temperature with the blocking buffer, 5% FBS in PBS, washed, and different concentrations of either pure CD200Fc (standard curve) or plasma samples (diluted 1:4 in blocking buffer) were added. Plates were incubated for 2 hours at room temperature, followed by 2-hours of incubation with the detection antibody (rabbit anti-CD200Fc or rabbit anti-CD200v+c) at a 1:2000 dilution.
Goat anti-rabbit IgG-HRP antibody at a 1:12,500 dilution was added and plates incubated at room temperature for 30 minutes. At least 5 washes with wash buffer (PBS+0.01% Tween20) were performed between each step. After the final wash, TMB substrate was added. All reactions were stopped by addition of 50μl 0.2M sulfuric acid per well after 5 minute of incubation at room temperature in the dark. All plates were read at 450nm in a Multiskan Ascent 96/384 plate reader (MTX Lab Systems, Vienna, VA).
Engraftment of human CLL splenocytes in NSG mice
On the day of experimentation, mice received 2.4 Gy of γ-irradiation, followed by For immunohistochemistry an aliquot of fresh spleen tissue was fixed in 10% formalin and slides prepared and processed by the Pathology lab at Sunnybrook Health Science centre. Engraftment of CLL cells was analyzed by multi-color FACS staining using single cell suspensions and the various mAbs discussed above.
CD200 blockade, CD200Fc, and T cell depletion in vivo studies
For CD200 blockade experiments, mice were randomly assigned into 3 groups after infusion of human splenocytes. Two of the three groups received sCD200 hi CLL plasma while a third group received sCD200 absorbed CLL plasma. Of the two groups that received CLL plasma one group also received 50μg (iv) of Fab anti-CD200 mAb 1B9 the day after spleen cell injection, and on two subsequent occasions at 72 hour intervals. In experiments where CD200F was used, purified CD200Fc was prepared in normal plasma at a concentration of 50μg/ml, and was infused ip at the same dosing schedule as that of CLL plasma.
For T cell depletion experiments mice received human splenocytes and sCD200 hi CLL plasma, or sCD200 absorbed CLL plasma. The following day animals were randomly assigned to receive 20μg OKT3 (anti-CD3) antibody iv, with 2 additional infusions at 72 hour intervals.
In studies comparing the therapeutic efficiency of 1B9 and Rituxan, mice were engrafted with human splenocytes along with biweekly infusion of sCD200 hi plasma. 28 days following CLL infusion mice were randomly assigned to receive saline, 1B9 (50μg/mouse) or Rituxan (50mg/kg per mouse), all delivered iv in 300μl. All treatments were repeated at 72-hour intervals for a total of 4 treatments. Animals were sacrificed 8 days after the last treatment. For each in vivo experiment, mice of both sexes were used, with at least 3 mice per group. All experiments were repeated individually with splenocytes from at least two different patients.
FACS analyses
CD200 cell surface staining was performed using a rat anti-CD200 mAb (3G7) as previously described (6) . Multi-color FACS analyses were performed to characterize engrafted human cells. The optimal concentration of antibody for staining was determined individually for each antibody. Single color controls were included in each experiment for compensation purposes, and all samples were analyzed in a Coulter FC500 flow cytometer.
Statistics
Spearman's Rank Correlation test and a Man-Whitney U test were used to determine the correlation between sCD200 levels and various clinical markers in CLL.
All clinical analyses were done using SPSS Statistics software. For in vivo studies the absolute count of each engrafted cell population (CLL or T cells) was calculated from [total cell count x frequency], with frequency based on FACS staining profiles. Unpaired t-tests were used to determine significance between sample means. Analysis of in vivo studies was performed using GraphPad Prism 5.0 software.
Results
Identification of sCD200 in plasma from CLL patients
CD200 is normally considered a membrane molecule (20) . We have previously also exist in a soluble form in the plasma (6, 19) . To explore evidence for a plasma form of CD200 (sCD200), we established a sandwich ELISA using 1B9 as capture antibody and a rabbit anti-hCD200 detection polyclonal antibody (rabbit anti-hCD200Fc) as described in the Materials and Methods. The sensitivity of this ELISA using pure CD200Fc protein as standard was found to be 0.05ng/ml. CD200Fc was used to generate standard curves in the range 0.05-10ng/ml for quantitation of sCD200 in samples in all ELISA studies. The reproducibility and validity of sCD200 measurements was confirmed in a separate ELISA using a different antiserum (rabbit anti-hCD200v+c) as detection antibody. sCD200 levels in plasma from 25 healthy controls ranged from 0.4±0.2ng/ml. These levels were independent of age (20-64 years) or gender (data not shown). Elevated sCD200 levels were observed in plasma samples from CLL patients across all clinical stages (Fig 1a) .
Serum sCD200 levels are associated with disease stage in CLL
While CD200 expression was detected on CLL cells from all individuals in a cohort of 25 patients at various stages of disease, the cell surface expression level was not correlated with either tumor burden or other clinical parameters of disease (6) . To determine whether sCD200 levels correlated with CLL clinical parameters, plasma samples obtained at diagnosis from 82 CLL patients were tested in the sandwich ELISA for sCD200 levels. The patient age in this cohort ranged from 38-91 (median age 61).
Correlation analyses were performed to compare sCD200 levels with other parameters linked to clinical outcome in CLL (see Table 1 for patient details).
Independent of the expression of CD200 on the cell surface, sCD200 levels were correlated with tumor burden (see supplementary table I), with patients in later stages of disease (Rai stage III and IV) having significantly higher sCD200 levels than patients at early stages (Fig 1b) . In general clinical treatment of CLL is reserved for patients with late disease and/or rapidly progressive disease (21) . Using the number of treatments received by each patient in our cohort, regardless of the nature of that treatment, as a surrogate marker for aggressive disease, we pooled patients into groups who had received two or more courses of treatments vs. those with no (or only 1 course of) treatment. The former had significantly higher serum sCD200 levels than those with more indolent disease as defined by no treatment (p<0.0001, Fig 1c) or only 1 treatment (p=0.0027, Fig 1c) .
Of the conventional prognostic markers for CLL, sCD200 levels correlated most strongly with serum β 2 microglobulin levels (p<0.0001, Fig 1d) . CD38 expression levels did not correlate with sCD200 levels (22) . 
Development of a xenograft model for CLL
Given that sCD200 levels were higher in patients with late stage and/or aggressive disease, we hypothesized that sCD200 in CLL plasma might play a role in vivo in fostering CLL growth. In a series of preliminary studies we infused 1x10 (24, 25) . We considered that a possible explanation for this poor engraftment might be the absence of supporting cells that would be present in proliferation centers but not in the blood.
In an attempt to provide a proposed "microenvironment factor", we next attempted reconstitution of mice with splenocytes harvested from CLL patients ( Table 2 (Fig 3a, day 28; Fig 3b, day 54) . This difference was particularly pronounced in the peritoneal cavity compartment (p=0.003, Fig 3b) . As noted, splenocytes produced greater engraftment of CLL cells in both the spleen and peritoneal cavity of NSG recipients compared to engraftment seen using PBL (data not shown). Substantial patient-to-patient variability was observed in engraftment of both CLL and T cells (Fig 3b and c , engraftment of spleens 1 and 5 shown).
Accordingly in all subsequent studies described detailed analysis was restricted to use of frozen aliquots of splenocytes from only 3 patients (spleens 1, 5, and 6) Characterization of CLL in humanized NSG mice H&E staining of spleen tissue taken from mice at day 54 showed aggregates of small-lymphocytes resembling proliferation centers by H&E staining that were absent in control animals (Fig 3d, upper panel) . CD20 + CLL cells were also more abundant in the spleen of experimental animals by immunohistochemistry (Fig 3d, middle panel) . All CLL cells found in the peritoneal cavity and spleen of both experimental and control groups expressed CD40, CD38, and CD200 at similar levels to the starting population (data not shown). 
Moreover, splenic CLL cells co-localized with T cells by immunohistochemistry, in a pattern reminiscent of that observed in proliferation centers and in the spleen of CLL patients themselves (Fig 2b and 3d) (28) . Note that T cells were found in the spleens of mice injected with normal plasma, although CLL cells did not engraft in this case (Fig 3-3d, lower panel) . Engraftment of cells other than CLL and T cells was minimal regardless of the source of plasma.
In a study monitoring longer-term engraftment, in which biweekly infusion of CLL plasma was continued to 1 week before experimental endpoint, we observed persistence of CLL cells in both peritoneal cavity (PC) and spleen at 70 days post spleen cell infusion (Fig 3e, engraftment of spleen 6 shown). Engrafted CLL cells express the CLL markers CD19, CD5, and CD200 (Fig 3e) , as well as CD40, CD20, and CD38 at levels similar to that on CLL cells from the original spleen (supplementary Fig 2) . In contrast, increased expression of CD49d was detected in a subpopulation of engrafted CLL cells (supplementary Fig 2) . Engrafted human CD45 3) .
Anti-CD200 and OKT3 mAbs abrogate engraftment of CLL in NSG mice
To assess whether sCD200 in CLL plasma was an important factor contributing to engraftment of CLL cells in vivo, animals receiving CLL splenocytes and sCD200 hi serum also received Fab anti-CD200 mAb 1B9. An independent group of mice received CLL splenocytes and CLL plasma that had been depleted of CD200 by passage though an anti-CD200 CNBr column. sCD200 absorption from the serum was confirmed independently by ELISA (>97% depletion). Both anti-CD200 mAb and depletion of , Fig 4b) . The effect of CD200Fc for engraftment in peritoneal cavity was less pronounced, although followed a similar pattern to that shown for spleen (supplementary Fig 5) . CD200 is known to deliver downstream signals through a receptor CD200R, and we had previously reported that CD200R was detected mostly on splenic CD4 
Comparison of anti-CD200 and rituximab in eliminating engrafted CLL cells
In a final study we asked whether CD200 blockade could eliminate engrafted CLL cells, thus highlighting CD200 as a potential therapeutic target. Specifically we compared the efficacy of Rituxan, a clinically approved monoclonal antibody targeting CD20 on CLL cells, with anti-CD200 mAb therapy as treatment in mice with established spleen-cell derived CLL engraftment (30) .
At 28 days following CLL splenocyte injection and biweekly sCD200 hi CLL serum infusion, independent groups of mice received Rituxan (50μg/mouse) or Fab antimouse CD200 mAb (iv). A total of 4 injections were given, at 72-hr intervals over 2 weeks. Animals were maintained for 10 days after the last dose of treatment, again with ongoing injection of CLL serum on a biweekly basis, and were sacrificed at day 45.
FACS analyses on cell suspensions harvested from the spleen and peritoneal cavity of these animals showed that both rituxan (p=0.0026) and anti-CD200 mAb (p=0.0057) were effective in reducing CLL engraftment in both tissue compartments (Fig 5a and b) .
Essentially all CLL cells engrafting in the peritoneal cavity were depleted, with significant attenuation of engraftment in the spleen (>70%). Although the overall frequency of CD3 + T cells in either compartment did not seem to be significantly affected (Fig 5c) , the CD4:CD8 ratio in mice treated with either Rituxan or anti-CD200 mAb differed from that in untreated mice (supplementary Fig 7) .
Discussion
The studies described in this chapter implicate a novel soluble form of CD200 (sCD200) in the progression of CLL. sCD200 is present at high levels in CLL plasma CD200 expression has been linked with outcome in many malignancies (3, 31, 32) . Biochemical analysis has suggested that sCD200 is likely shed from the cell surface by proteolytic cleavage, with the ADAM family of proteases being prime candidates in this mechanism (supplementary Fig 1; Wong K, manuscript in preparation). We found that plasma sCD200 levels, but not surface expression of CD200 on CLL cells, correlated strongly with tumor burden, disease stage, and an aggressive disease course as reflected in the requirement for multiple treatments. Plasma sCD200 was also correlated with plasma β 2 microglobulin levels, known to be an independent predictor of progression-free survival and overall survival in CLL (33, 34) . The value of plasma sCD200 as an independent prognostic marker against current clinical prognostic markers remains to be determined.
The hypothesis that sCD200 is important in CLL disease is supported by evidence plasma pooled from healthy volunteers with ten-fold lower sCD200 levels (~ 0.5ng/ml).
Those CLL cells which engraft in both sets of animals express CD20, CD40, CD23, CD38 and CD200 at levels similar to the CLL cells from the starting spleen population, suggesting no selection for survival of unique subpopulations occurred in vivo under these conditions. Interestingly, an increase in the expression of CD49d, α4 subunit of the lymphocyte integrin VLA-4, which has been shown to play a role in CLL homing to bone marrow in vivo, was observed in a subpopulation of CLL cells in both spleen and peritoneal cavity at 70 days post-reconstitution (37) . Since few CLL cells engraft in the bone marrow, the significance of this CD49d expression remains unclear.
Engraftment of CLL cells in a xeno-microenvironment often reflects persistence of donor cells, rather than proliferation of CLL cells in the host, and engrafted CLL cells gradually decline with time (24, 25, 36) . The use of EBV-transformed CLL cell lines circumvents this issue, although these lines often exhibit very different biologic properties from those of primary cells, particularly with the absence of CD5 expression (35, 38) . In contrast, we did not observe a significant decline in the absolute number of engrafted CLL cells from day 25 to day 70 (data not shown). It remains to be determined whether CLL engraftment in our model reflects both survival and in vivo proliferation of CLL cells.
Since the engrafted CLL cells continue to express CD200 at high levels, it is possible that sCD200 may be released in ongoing fashion from grafted CLL cells in vivo-this hypothesis is supported by recent findings from assaying sCD200 levels in mice at >6 months post-reconstitution (unpublished data). We have not investigated whether continual infusion of sCD200 (15, 39, 40) . While we do not rule out contributions by other factors besides sCD200 in the support of CLL growth, two lines of evidence from this study supports the hypothesis that sCD200 is a key contributor. First, pre-absorption of sCD200 from CLL plasma minimized CLL engraftment. Second, addition of exogenous CD200Fc, a soluble, recombinant form of CD200, to sCD200 lo normal plasma, which by itself had no effect on CLL engraftment, resulted in enhanced CLL in vivo survival.
Our data also supports a role for T cell involvement in this mechanism of action, In summary, our data suggests that sCD200, present in patient plasma, is associated with disease progression in CLL patients, and its presence can be utilized to establish a novel xenograft model for CLL which may be useful for preclinical testing. • CVP, cyclophosphamide/vincristine/prednisone; CHOP, cyclophosphamide/vincristine/doxorubicin/prednisone; DHAP, dexamethasone/ cytarabine/cisplatin; FC, fludarabine/cyclophosphamide; C, Chlorambucil; P, prednisone; F, fludarabine; R, rituximab; Revl, revlimid (lenalidomide); S, solumedrol; Splen, splenectomy Both groups of animals were subdivided to receive either OKT3 iv for T cell in vivo depletion, or control saline. OKT3 was given a total of 4 times in two weeks. T cell depletion appeared to abrogate CLL engraftment regardless of the presence of sCD200 in supplemented plasma. Data from 1 representative experiment using sp1, with engraftment of CLL cells in mouse peritoneal cavity is shown (mouse spleens showed similar engraftment pattern). CLL engraftment in was assessed by CD19, CD5, and CD200 staining. Mice were sacrificed at day 21 for a) and c), and at day 54 for b). 
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